News
Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...
We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Novo Nordisk A/S (NYSE:NVO) is one of the stocks Jim Cramer recently discussed. Novo Nordisk A/S (NYSE:NVO ...
Gabapentin, which is used to treat seizures, nerve pain and restless leg syndrome might be linked with increased risk of ...
A labeling mistake has led to a nationwide recall of four different types of Ritz peanut butter cracker sandwich cartons, ...
Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...
On June 25, 2025, two securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of ...
3d
Asianet Newsable on MSNHims & Hers Announces Plans To Expand Into Canada As Novo Nordisk’s Weight Loss Drug Patent ExpiresThe telehealth company stated that its entry to Canada will come as generic Semaglutide hits the market for the first time.
The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired Hims ...
Hims and Hers announced this morning that it will begin offering compounded semaglutide (generic Ozempic or Wegovy) for $199 ...
Hims & Hers announced plans to expand its weight loss program to Canada in 2026 in connection with the availability of generic semaglutide anywhere in the world.
The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results